Analysts predict that Johnson & Johnson (NYSE:JNJ) will report $20.09 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Johnson & Johnson’s earnings, with the highest sales estimate coming in at $20.22 billion and the lowest estimate coming in at $19.96 billion. Johnson & Johnson posted sales of $20.35 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 1.3%. The company is scheduled to issue its next earnings results on Tuesday, October 15th.
According to Zacks, analysts expect that Johnson & Johnson will report full-year sales of $81.51 billion for the current fiscal year, with estimates ranging from $81.23 billion to $81.99 billion. For the next financial year, analysts expect that the company will post sales of $85.43 billion, with estimates ranging from $84.23 billion to $86.01 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The company had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same quarter last year, the company posted $2.10 earnings per share. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year.
Several research analysts recently commented on JNJ shares. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Barclays initiated coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price target for the company. Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective on the stock. in a research note on Thursday, July 18th. Finally, Credit Suisse Group set a $156.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $150.60.
Shares of NYSE JNJ traded up $1.62 during trading hours on Friday, hitting $131.17. 5,885,667 shares of the stock were exchanged, compared to its average volume of 7,115,274. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company’s 50 day moving average is $130.11 and its 200 day moving average is $135.97. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The firm has a market capitalization of $335.04 billion, a P/E ratio of 16.04, a P/E/G ratio of 2.15 and a beta of 0.68.
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $0.95 dividend. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 annualized dividend and a yield of 2.90%. Johnson & Johnson’s dividend payout ratio is 46.45%.
Several large investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $25,000. Krane Funds Advisors LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at $26,000. Crewe Advisors LLC lifted its position in shares of Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after acquiring an additional 196 shares during the period. Evolution Wealth Advisors LLC bought a new position in Johnson & Johnson during the fourth quarter worth $40,000. Finally, Permanens Capital L.P. boosted its stake in Johnson & Johnson by 50.0% during the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 72.12% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.